SPARC inches up on granting exclusive license to Tripoint Therapeutics LLC, USA

22 Sep 2020 Evaluate

Sun Pharma Advanced Research Company is currently trading at Rs. 169.55, up by 0.65 points or 0.38% from its previous closing of Rs. 168.90 on the BSE.

The scrip opened at Rs. 174.95 and has touched a high and low of Rs. 174.95 and Rs. 169.05 respectively. So far 29161 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 210.70 on 28-Jan-2020 and a 52 week low of Rs. 81.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 186.70 and Rs. 168.05 respectively. The current market cap of the company is Rs. 4425.98 crore.

The promoters holding in the company stood at 68.46%, while Institutions and Non-Institutions held 3.11% and 28.43% respectively.

Sun Pharma Advanced Research Company (SPARC) has granted an exclusive license to Tripoint Therapeutics LLC, USA (Tripoint) to commercialize Elepsia XR 1000 mg and Elepsia XR 1500 mg tablets in the USA.

Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for Elepsia XR 1000 mg and Elepsia XR 1500 mg. The initial term of the agreement shall be 5 years and may be further extended as per mutual agreement between the parties.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

134.45 0.70 (0.52%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 643.75
Indegene 519.25
CMS Info Systems 339.55
Sagility 52.19
Smartworks Coworking 476.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×